Exercise reduces the risk of hepatic steatosis, fibrosis, and hepatocellular carcinoma in a dose-dependent manner in individuals with MASLD.
The paper reports that exercise is associated with a dose-dependent reduction in the risk of hepatic steatosis, fibrosis, and hepatocellular carcinoma in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). This effect is partly independent of weight loss, and lifestyle interventions including exercise improve cardiometabolic health beyond the liver.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Exercise reduces the risk of hepatic steatosis, fibrosis, and hepatocellular carcinoma in a dose-dependent manner in individuals with MASLD. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
Exercise reduces the risk of hepatic steatosis, fibrosis, and hepatocellular carcinoma in a dose-dependent manner in individuals with MASLD.
This conclusion is most relevant to: Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), with or without obesity.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Non-pharmacological treatment of MASLD. (Diabetologia, 2026) —
How It Works
The proposed biological pathway:
- ▸Exercise reduces hepatic fat accumulation
- ▸Improves insulin sensitivity and metabolic function
- ▸Decreases inflammation and fibrosis progression
- ▸Result: Reduced risk of steatosis, fibrosis, and hepatocellular carcinoma
Who Might Benefit
Evidence fit by population:
- ▸Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), with or without obesity
Recommended Dose
N/A (dose-dependent but specific dose not quantified)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Adherence to lifestyle interventions is suboptimal, especially long-term
- ▸Variability in individual response to exercise requires further research on biomarkers for personalized approaches
Frequently Asked Questions
What type of exercise is recommended for MASLD?▼
The abstract does not specify exercise type, but it emphasizes dose-dependent benefits and combining exercise with energy restriction for weight loss.
Is weight loss necessary for exercise to benefit MASLD?▼
No, the effects of exercise are partly independent of weight reduction, though weight loss remains the cornerstone of non-pharmacological strategies.
How much exercise is needed to reduce liver cancer risk in MASLD?▼
The abstract states a dose-dependent reduction in risk but does not provide specific exercise amounts or durations.
Can exercise alone reverse liver fibrosis in MASLD?▼
The abstract suggests exercise reduces the risk of fibrosis, but does not claim reversal; it is part of a broader lifestyle intervention.
References
- 1.Dufour JF, Berzigotti A. “Non-pharmacological treatment of MASLD..” Diabetologia, 2026. PMID: 42502137 DOI: 10.1007/s00125-026-06811-5